SHANGHAI: China launched the country's first class-action lawsuit against a listed company on Friday, targeting Kangmei Pharmaceutical Co, as regulators vowed "zero tolerance" against accounting fraud and other capital markets "tumors".
Saif Ali Khan Health Update
The China Securities Investor Service Centre (CSISC), a government-affiliated body, is suing Kangmei on behalf of more than 50 individual investors in a landmark case in China's capital markets, the
China Securities Regulatory Commission
(
CSRC
) said.
Kangmei was engaged in intentional and systematic financial cheating worth 30 billion yuan ($4.60 billion) between 2016 and 2018, CSRC said, adding "toxic tumors" in capital markets must be eradicated swiftly, and relentlessly.
Kangmei could not be immediately reached for comment outside business hours.
China introduced the class-action mechanism to capital markets last year as part of efforts to crack down on corporate malfeasance and bolster investor confidence.
Although
corporate fraud
is not uncommon in China, retail investors have historically had little chance to make their voices heard. Small investors often likened legal action to ants fighting elephants.
Still, CSRC said on Friday that the new class
action mechanism
would greatly reduce investors' cost of suing listed companies and help reduce malpractices in China's capital market.
Unlike the US system, class actions must be launched by government bodies such as CSISC, and only typical and major cases are selected initially.
Stay informed with the latest Business News on Times of India. Explore the list of Bank Holidays, stay informed about Budget 2025, discover the new Income Tax Slabs, and use the Income Tax Calculator for hassle-free tax planning.
Unlock Investment Potential: Enroll in ET's Stock Valuation Workshop - Batch 3. Secure Your Spot Now!